Search Results

Mahana Therapeutics, a leading provider of digital chronic condition management programs, announced that it has acquired Berlin-based HiDoc Technologies GmbH, operating as Cara Care, a leader in digital digestive healthcare.

Mahana Therapeutics, a leading provider of prescription digital therapeutics, announced that the company has entered into a multi-million-dollar distribution and marketing partnership with the Consumer Health division of Bayer to commercialize digital therapeutics.

Mahana Therapeutics announced compelling results from the analysis presented by Mythili Pathipati, M.D. of Mass General Hospital at ACG 2023 Scientific Meeting in Vancouver on October 24, 2023 demonstrating that nearly 60% of users who completed Mahana IBS in the real world setting reported clinically meaningful reduction in severity of IBS symptoms.

Mahana Therapeutics today announced that it has completed Service Organization Control (SOC) 2 Type II audit for its world class digital therapeutic offering.

Mahana Therapeutics, a leading provider of prescription digital therapeutics, announced today that analysis performed by Mass General Hospital led by Kyle Staller, M.D., has been accepted for presentation at the upcoming ACG 2023 Scientific Meeting in Vancouver on October 24, 2023.

Mahana Therapeutics, a leading developer of digital therapeutics designed to empower people with chronic conditions to lead fuller lives, today announced the appointment of Justin Zamirowski, Jr. as chief commercial officer.

Mahana Therapeutics, a leading developer of prescription digital therapeutics designed to empower people living with chronic health conditions, today announced that Mahana has been selected for the DigitalHealth.London’s Accelerator programme.

Mahana Therapeutics has completed a $61 million Series B financing.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system